Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab
Information source: University of Sao Paulo
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Macular Edema; Diabetic Retinopathy; Macular Degeneration
Intervention: bevacizumab (Drug); anterior chamber paracentesis (Procedure); acetazolamide (Drug); brimonidine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: University of Sao Paulo
Summary
Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral
acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal
bevacizumab injection (IVBV).
Methods: 47 patients scheduled for IVBV (1. 5 mg / 0. 06 ml) will be randomly assigned to a
pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes),
anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine
tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP
will be measured 90 minutes before injection (baseline), just before injection, and at 3,
10, 20 and 30 minutes after the procedure.
Clinical Details
Official title: Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection: Preliminary Results
Study design: N/A
Primary outcome: Intra-ocular pressure variation after intra-vitreous injection of bevacizumab
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- macular edema
Exclusion Criteria:
- pulmonary chronic problems
- chronic renal failure
- intraocular inflammation
- drug or alcohol addiction
Locations and Contacts
School of Medicine - Clinical Hospital, Ribeirao Preto, SP 14049-900, Brazil
Additional Information
Last updated: December 8, 2008
|
